(Q38406393)

2 September 2017

1 reference

title

Azole antifungals: 35 years of invasive fungal infection management (English)

1 reference

invasive fungal infections

2 September 2017

1 reference

4

John Perfect

1 reference

2 September 2017

David Allen

1

1 reference

PubMed ID

25843556

2 September 2017

Dustin Wilson

series ordinal

2

1 reference

PubMed ID

25843556

2 September 2017

Richard Drew

series ordinal

3

1 reference

2 September 2017

5 April 2015

1 reference

Expert Review of Anti-infective Therapy

2 September 2017

1 reference

2 September 2017

13

1 reference

2 September 2017

6

1 reference

2 September 2017

787-798

1 reference

Epidemiology and treatment of mucormycosis

2 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Epidemiology and clinical manifestations of mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Strategies in the treatment of systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Clotrimazole: a review of its antifungal activity and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Deep infections from Petriellidium boydii treated with miconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Cardiorespiratory toxicity due to miconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

The influence of gastric acidity on the bio-availability of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Drug safety assessment of oral formulations of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Ketoconazole Blocks Adrenal Steroid Synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

History of the development of azole derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Triazole antifungal agents in invasive fungal infections: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

The changing epidemiology of healthcare-associated candidemia over three decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Advances in antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

New and investigational triazole agents for the treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Pharmacology and clinical use of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Alopecia and nail changes associated with voriconazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Optimising absorption of posaconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Use of Antifungal Combination Therapy: Agents, Order, and Timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole salvage treatment for invasive fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Recent advances in the treatment of life-threatening, invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

New and emerging treatments for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

A randomized, double-blind, multiple-dose, placebo-controlled, dose escalation study with a 3-cohort parallel group design to investigate the tolerability and pharmacokinetics of albaconazole in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2015.1032939

10.1586/14787210.2015.1032939

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

25843556